260 related articles for article (PubMed ID: 21447659)
1. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
Defronzo RA
Diabetes Care; 2011 Apr; 34(4):789-94. PubMed ID: 21447659
[No Abstract] [Full Text] [Related]
2. Bromocriptine (Cycloset) for type 2 diabetes.
Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):97-8. PubMed ID: 21344781
[No Abstract] [Full Text] [Related]
3. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
Chamarthi B; Cincotta AH
Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
[TBL] [Abstract][Full Text] [Related]
4. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
Schwartz SS; Zangeneh F
Postgrad Med; 2016 Nov; 128(8):828-838. PubMed ID: 27458683
[TBL] [Abstract][Full Text] [Related]
5. Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR.
Bell DS
Postgrad Med; 2012 Sep; 124(5):121-35. PubMed ID: 23095432
[TBL] [Abstract][Full Text] [Related]
6. Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
Chamarthi B; Gaziano JM; Blonde L; Vinik A; Scranton RE; Ezrokhi M; Rutty D; Cincotta AH
J Diabetes Res; 2015; 2015():157698. PubMed ID: 26060823
[TBL] [Abstract][Full Text] [Related]
7. Bromocriptine: old drug, new formulation and new indication.
Holt RI; Barnett AH; Bailey CJ
Diabetes Obes Metab; 2010 Dec; 12(12):1048-57. PubMed ID: 20977575
[TBL] [Abstract][Full Text] [Related]
8. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.
Roe ED; Chamarthi B; Raskin P
J Diabetes Res; 2015; 2015():834903. PubMed ID: 26060825
[TBL] [Abstract][Full Text] [Related]
9. Bromocriptine mesylate (Cycloset) for type 2 diabetes mellitus.
Weiland CM; Hilaire ML
Am Fam Physician; 2013 May; 87(10):718-20. PubMed ID: 23939451
[No Abstract] [Full Text] [Related]
10. Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.
Scranton R; Cincotta A
Expert Opin Pharmacother; 2010 Feb; 11(2):269-79. PubMed ID: 20030567
[TBL] [Abstract][Full Text] [Related]
11. Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma.
Igata M; Yagi Y; Hanatani S; Sakaguchi M; Ishii N; Yoshinaga K; Kawashima J; Motoshima H; Araki E
J Diabetes Investig; 2021 Apr; 12(4):668-671. PubMed ID: 32706496
[TBL] [Abstract][Full Text] [Related]
12. Bromocriptine: its place in type 2 diabetes Tx.
Sando KR; Taylor J
J Fam Pract; 2011 Nov; 60(11):E1-5. PubMed ID: 22049355
[TBL] [Abstract][Full Text] [Related]
13. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
Lamos EM; Levitt DL; Munir KM
Prim Care Diabetes; 2016 Feb; 10(1):60-5. PubMed ID: 26670921
[TBL] [Abstract][Full Text] [Related]
14. Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus.
Siamashvili M; Davis S
Expert Opin Pharmacother; 2021 Feb; 22(2):241-247. PubMed ID: 33030357
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus.
Kabir MT; Ferdous Mitu J; Akter R; Akhtar MF; Saleem A; Al-Harrasi A; Bhatia S; Rahman MS; Damiri F; Berrada M; Rahman MH
Environ Sci Pollut Res Int; 2022 Jul; 29(31):46385-46404. PubMed ID: 35486279
[TBL] [Abstract][Full Text] [Related]
16. Effects of the D2 receptor agonist bromocriptine on sleep bruxism: report of two single-patient clinical trials.
Lobbezoo F; Soucy JP; Hartman NG; Montplaisir JY; Lavigne GJ
J Dent Res; 1997 Sep; 76(9):1610-4. PubMed ID: 9294496
[TBL] [Abstract][Full Text] [Related]
17. Equivalent doses of ropinirole and bromocriptine.
Jost WH
Eur J Neurol; 1999 Sep; 6(5):618. PubMed ID: 10866496
[No Abstract] [Full Text] [Related]
18. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.
Gaziano JM; Cincotta AH; Vinik A; Blonde L; Bohannon N; Scranton R
J Am Heart Assoc; 2012 Oct; 1(5):e002279. PubMed ID: 23316290
[TBL] [Abstract][Full Text] [Related]
19. Dopamine: the forgotten felon in type 2 diabetes.
Kalra S; Kalra B; Agrawal N; Kumar S
Recent Pat Endocr Metab Immune Drug Discov; 2011 Jan; 5(1):61-5. PubMed ID: 22074579
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Krysiak R; Gilowski W; Szkrobka W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):282-7. PubMed ID: 26146893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
